Relationships between homocysteine and related amino acids in chronic hemodialysis patients

Clinical Nephrology

Volumn 55, Issue 6, 2001, Pages 465-470

  McDonald, S P ^a   Whiting, M J ^a   Tallis, G A ^a   Barbara, J A J ^a  

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

Author keywords

Folate; Glycine; Homocysteine; Methionine; Serine

Indexed keywords

AMINO ACID; CYANOCOBALAMIN; FOLIC ACID; GLYCINE; HOMOCYSTEINE; METHIONINE; SERINE;

AMINO ACID BLOOD LEVEL; AMINO ACID SYNTHESIS; ARTICLE; ATHEROSCLEROSIS; CLEARANCE; CLINICAL LABORATORY; CLINICAL OBSERVATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ERYTHROCYTE; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; RISK FACTOR; VASCULAR DISEASE;

AMINO ACIDS; ERYTHROCYTES; FOLIC ACID; HOMOCYSTEINE; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; VITAMIN B 12;

EID: 0034981044     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients
2. The effect of reduced glomerular filtration rate on plasma total homocysteine concentration
3. Oral folate enhances endothelial function in hyperhomocysteinemic subjects
4. Plasma concentration of asymmetric dimethylarginine, and endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholestrolemia
5. Net uptake of plasma homocysteine by the rat kidney in vivo
6. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in endstage renal disease patients on dialysis: A case-control study
7. High dose B vitamin treatment of hyperhomocysteinemia in dialysis patients
8. Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients
9. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study
10. Folic acid - An innocuous means to reduce plasma homocysteine
11. Acute hyperhomocysteinemia and endothelial dysfunction
12. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: An effect reversible with vitamin C therapy
13. Long-term folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine level in chronic renal failure
14. Vitamin supplementation reduces blood homocysteine levels: A controlled trial in patients with venous thrombosis and healthy volunteers
15. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis
16. Homocysteinemia: Depressed plasma serine levels
17. Characterization of homocysteine metabolism in the rat kidney
18. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease
19. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis
20. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease
21. Homocysteine, a new cardiovascular risk factor, is also a powerful uremic toxin
22. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations
23. Association between plasma homocysteine concentrations and extracranial carotid artery carotid-artery surgery
24. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians
25. Total, free, and protein-bound sulphur amino acids in uremic patients
26. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients
27. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: Results of the Vienna multicenter study
28. Vitamin C improves endothelium-dependent vasodilation in forearm resistance vessels of humans with hypercholesterolemia
29. No net renal extraction of homocysteine in fasting humans
30. Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: No change in endothelial function after long-term therapy
31. Homocysteine methionine metabolism in ESRD: A stable isotope study
32. Homocysteine and vascular disease
33. Influence of folic acid on postprandial endothelial dysfunction
34. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans